PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
17157900-7	2007	After coronary stenting, the rise in CRP levels was significantly higher in controls than those treated with naproxen (DeltaCRP=6.4 mg/L in the controls and 0.43 mg/L in the naproxen group, p<0.0001).	Naproxen	109-117	C-reactive protein	Homo sapiens	37-40	
22833186-10	2012	However, the nonselective NSAID naproxen was associated with a significant decrease in the CRP level, whereas the cyclooxygenase 2-selective NSAID lumiracoxib was associated with a significant increase in the CRP level.	Naproxen	32-40	C-reactive protein	Homo sapiens	91-94	
20861716-8	2012	The naproxen-alone group showed significant elevations in CRP, alanine transaminase, and aspartate transaminase when compared with the other groups.	Naproxen	4-12	C-reactive protein	Homo sapiens	58-61	
7685226-6	1993	CRP concentrations in naproxen-treated and placebo patients were essentially unchanged.	Naproxen	22-30	C-reactive protein	Homo sapiens	0-3	
17157900-7	2007	After coronary stenting, the rise in CRP levels was significantly higher in controls than those treated with naproxen (DeltaCRP=6.4 mg/L in the controls and 0.43 mg/L in the naproxen group, p<0.0001).	Naproxen	174-182	C-reactive protein	Homo sapiens	37-40	
17157900-10	2007	CONCLUSION: Our data show that naproxen pretreatment leads to significant suppression in PCI related CRP elevation.	Naproxen	31-39	C-reactive protein	Homo sapiens	101-104